Interaction Color Code
Clinical Bottom Line
Do not coadminister: Increased levels of rifabutin, reduced levels of elvitegravir
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
Cmax decreased 9%, AUC decreased 21%, Cmin decreased 67%
Drug 2
Drug 2 dose
150 mg every other day
Drug 2 effect
No significant change in rifabutin Cmin, AUC, or Cmax. 25-O-desacetylrifabutin metabolite Cmax increased 384%, AUC increased 625%, Cmin increased 394% as compared to 300 mg rifabutin alone.
Clinical Effects
Increased rifabutin effects, potential loss of antiretroviral activity
Management
Use alternative agents
Import ID
135
